Venturelab: Switzerland, land of biotech - 10 Swiss biotech startups to watch in 2020

Swiss biotech startups are considered among the most promising and innovative companies in the world. Big industry players have already acquired many Biotech startups and large transactions had a relevant impact on the entire Swiss ecosystem. The practice of medicine has changed dramatically over the past years and we all know that the healthcare systems are becoming more complex and more expensive. Much of that progress is likely to result from advances in personalized medicine. This new treatment paradigm aims to ensure that patients get the therapies best suited to their specific genetic conditions.

Millions of patients worldwide continue to benefit from biotech therapeutics developed by startups that are discovering, developing, and delivering innovative medicines to treat illnesses. For example, Crispr Therapeutics (IPO), Redvax (acquired by Roche), Covagen (acquired by J&J) and Amal Therapeutics (acquired by Boehringer Ingelheim) can be considered among the most successful Swiss biotech startups in the country. As startups in Switzerland continue to develop new medicines that address significant unmet needs, future innovations in healthcare research will bring exciting new advances to help millions of people worldwide.

10 Swiss Biotech Startups to Watch in 2020

• Araris Biotech AG: Enabling highly efficient and easy to manufacture antibody-drug conjugates (ADCs)
• Cutiss AG: grows human skin in the lab for patients that suffer from skin defects (e.g. burns).
• Elthera AG: is developing antibodies against the novel target L1CAM, an adhesion molecule whose expression is strongly correlated with an aggressive tumor phenotype and poor prognosis in various types
• InterAx Biotech AG: is uniquely positioned to assist drug candidate design and selection by integrating bioanalytical and computational pharmacology in collaborative projects with Biotech and Pharma companies
• Nagi Bioscience SA: aims to revolutionize the way toxic and/or beneficial effects of substances are tested today, by combining the use of microscopic worms as in vivo models for drug/chemical screening
• Resistell AG: their rapid AST solution addresses one of the biggest threats to global health today – Antimicrobial Resistance (AMR)
• Scailyte AG: develops artificial intelligence (AI) technology for biomedical research, pharmaceutical discovery and precision diagnostics
• TOLREMO therapeutics AG: developsof resistance-breaking cancer therapies
• Versantis AG: develops orphan drugs in liver and pediatric diseases
• Volumina Medical SA: is active in the field of tissue engineering and develops injectable 3D scaffolds for the reconstruction of volumes of soft tissues (fat, muscles, glandular tissues, supporting and connective